Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Development of the Everyday Conversational Sentences in Noise test.

Miles KM, Keidser G, Freeston K, Beechey T, Best V, Buchholz JM.

J Acoust Soc Am. 2020 Mar;147(3):1562. doi: 10.1121/10.0000780.

PMID:
32237858
2.

Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-126(27L)-35.

Tarbe M, Miles JJ, Edwards ESJ, Miles KM, Sewell AK, Baker BM, Quideau S.

ChemMedChem. 2020 Mar 11. doi: 10.1002/cmdc.202000038. [Epub ahead of print]

PMID:
32162475
3.

Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma.

Elbanna M, Orillion AR, Damayanti NP, Adelaiye-Ogala R, Shen L, Miles KM, Chintala S, Ciamporcero E, Ramakrishnan S, Ku SY, Rex K, Caenepeel S, Coxon A, Pili R.

Mol Cancer Ther. 2020 Jan;19(1):147-156. doi: 10.1158/1535-7163.MCT-18-1202. Epub 2019 Oct 3.

PMID:
31582532
4.

Evaluation of the Omron HEM-907 automated blood pressure device: comparison with office and ambulatory blood pressure readings.

D'Sa L, Senaratne N, Woodcock-Smith J, Miles KM, Wilkinson IB, McEniery CM.

Hypertens Res. 2019 Jan;42(1):52-58. doi: 10.1038/s41440-018-0120-7. Epub 2018 Oct 30.

PMID:
30374040
5.

Introducing an electronic tracking tool into daily multidisciplinary discharge rounds on a medicine service: a quality improvement project to reduce length of stay.

Meo N, Paul E, Wilson C, Powers J, Magbual M, Miles KM.

BMJ Open Qual. 2018 Jul 21;7(3):e000174. doi: 10.1136/bmjoq-2017-000174. eCollection 2018.

6.

Neurologic Injury Predicts Plaintiff Award in Federal Cardiac Surgery Trials.

Hui DS, Miles KM, Lee R.

Ann Thorac Surg. 2018 Sep;106(3):691-695. doi: 10.1016/j.athoracsur.2018.03.061. Epub 2018 Apr 30.

PMID:
29723534
7.

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.

Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu CC, Chintala S, Orillion A, Miles KM, Shen L, Elbanna M, Ciamporcero E, Arisa S, Pettazzoni P, Draetta GF, Seshadri M, Hancock B, Radovich M, Kota J, Buck M, Keilhack H, McCarthy BP, Persohn SA, Territo PR, Zang Y, Irudayaraj J, Tao WA, Hollenhorst P, Pili R.

Cancer Res. 2017 Dec 1;77(23):6651-6666. doi: 10.1158/0008-5472.CAN-17-0899. Epub 2017 Oct 4.

8.

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.

Pili R, Liu G, Chintala S, Verheul H, Rehman S, Attwood K, Lodge MA, Wahl R, Martin JI, Miles KM, Paesante S, Adelaiye R, Godoy A, King S, Zwiebel J, Carducci MA.

Br J Cancer. 2017 Mar 28;116(7):874-883. doi: 10.1038/bjc.2017.33. Epub 2017 Feb 21.

9.

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.

Wei L, Chintala S, Ciamporcero E, Ramakrishnan S, Elbanna M, Wang J, Hu Q, Glenn ST, Murakami M, Liu L, Gomez EC, Sun Y, Conroy J, Miles KM, Malathi K, Ramaiah S, Anbarasu A, Woloszynska-Read A, Johnson CS, Conroy J, Liu S, Morrison CD, Pili R.

Oncotarget. 2016 Nov 22;7(47):76374-76389. doi: 10.18632/oncotarget.13062.

10.

Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing.

Wei L, Papanicolau-Sengos A, Liu S, Wang J, Conroy JM, Glenn ST, Brese E, Hu Q, Miles KM, Burgher B, Qin M, Head K, Omilian AR, Bshara W, Krolewski J, Trump DL, Johnson CS, Morrison CD.

BMC Med Genomics. 2016 Oct 19;9(1):64.

11.

HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma.

Ramakrishnan S, Ku S, Ciamporcero E, Miles KM, Attwood K, Chintala S, Shen L, Ellis L, Sotomayor P, Swetzig W, Huang R, Conroy D, Orillion A, Das G, Pili R.

BMC Cancer. 2016 Aug 9;16:617. doi: 10.1186/s12885-016-2604-7.

12.

IATROGENIC MICROCHIP ARTERIAL EMBOLISM IN A CHILEAN FLAMINGO (PHOENICOPTERUS CHILENSIS).

Olds JE, Ewing J, Arruda P, Kuyper J, Riedesel E, Miles KM.

J Zoo Wildl Med. 2016 Jun;47(2):686-90. doi: 10.1638/2015-0168.1.

PMID:
27468052
13.

Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib.

Wei L, Liu S, Conroy J, Wang J, Papanicolau-Sengos A, Glenn ST, Murakami M, Liu L, Hu Q, Conroy J, Miles KM, Nowak DE, Liu B, Qin M, Bshara W, Omilian AR, Head K, Bianchi M, Burgher B, Darlak C, Kane J, Merzianu M, Cheney R, Fabiano A, Salerno K, Talati C, Khushalani NI, Trump DL, Johnson CS, Morrison CD.

Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000380. doi: 10.1101/mcs.a000380.

14.

Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation.

Wang J, Papanicolau-Sengos A, Chintala S, Wei L, Liu B, Hu Q, Miles KM, Conroy JM, Glenn ST, Costantini M, Magi-Galluzzi C, Signoretti S, Choueiri T, Gallucci M, Sentinelli S, Fazio VM, Poeta ML, Liu S, Morrison C, Pili R.

Oncotarget. 2016 May 24;7(21):29901-15. doi: 10.18632/oncotarget.9093.

15.

YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage.

Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, Barrera G, Pili R.

Oncogene. 2016 Mar 24;35(12):1541-53. doi: 10.1038/onc.2015.219. Epub 2015 Jun 29.

16.

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature.

Gotink KJ, Broxterman HJ, Honeywell RJ, Dekker H, de Haas RR, Miles KM, Adelaiye R, Griffioen AW, Peters GJ, Pili R, Verheul HM.

Oncoscience. 2014 Dec 15;1(12):844-53. eCollection 2014.

17.

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.

Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, Buck M, Chintala S, Bjarnason GA, Pili R.

Mol Cancer Ther. 2015 Feb;14(2):513-22. doi: 10.1158/1535-7163.MCT-14-0208. Epub 2014 Dec 17.

18.

Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.

Miles KM, Seshadri M, Ciamporcero E, Adelaiye R, Gillard B, Sotomayor P, Attwood K, Shen L, Conroy D, Kuhnert F, Lalani AS, Thurston G, Pili R.

PLoS One. 2014 Nov 13;9(11):e112371. doi: 10.1371/journal.pone.0112371. eCollection 2014.

19.

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.

Ciamporcero E, Miles KM, Adelaiye R, Ramakrishnan S, Shen L, Ku S, Pizzimenti S, Sennino B, Barrera G, Pili R.

Mol Cancer Ther. 2015 Jan;14(1):101-10. doi: 10.1158/1535-7163.MCT-14-0094. Epub 2014 Nov 7.

20.

Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.

Shen L, Sundstedt A, Ciesielski M, Miles KM, Celander M, Adelaiye R, Orillion A, Ciamporcero E, Ramakrishnan S, Ellis L, Fenstermaker R, Abrams SI, Eriksson H, Leanderson T, Olsson A, Pili R.

Cancer Immunol Res. 2015 Feb;3(2):136-48. doi: 10.1158/2326-6066.CIR-14-0036. Epub 2014 Nov 4.

21.

Dietary protein restriction inhibits tumor growth in human xenograft models.

Fontana L, Adelaiye RM, Rastelli AL, Miles KM, Ciamporcero E, Longo VD, Nguyen H, Vessella R, Pili R.

Oncotarget. 2013 Dec;4(12):2451-61.

22.

T-cell receptor (TCR)-peptide specificity overrides affinity-enhancing TCR-major histocompatibility complex interactions.

Cole DK, Miles KM, Madura F, Holland CJ, Schauenburg AJ, Godkin AJ, Bulek AM, Fuller A, Akpovwa HJ, Pymm PG, Liddy N, Sami M, Li Y, Rizkallah PJ, Jakobsen BK, Sewell AK.

J Biol Chem. 2014 Jan 10;289(2):628-38. doi: 10.1074/jbc.M113.522110. Epub 2013 Nov 6.

23.

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.

Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U.

Clin Genitourin Cancer. 2013 Dec;11(4):477-83. doi: 10.1016/j.clgc.2013.05.005. Epub 2013 Jul 26.

24.

T-cell receptor specificity maintained by altered thermodynamics.

Madura F, Rizkallah PJ, Miles KM, Holland CJ, Bulek AM, Fuller A, Schauenburg AJ, Miles JJ, Liddy N, Sami M, Li Y, Hossain M, Baker BM, Jakobsen BK, Sewell AK, Cole DK.

J Biol Chem. 2013 Jun 28;288(26):18766-75. doi: 10.1074/jbc.M113.464560. Epub 2013 May 22.

25.

Peptide length determines the outcome of TCR/peptide-MHCI engagement.

Ekeruche-Makinde J, Miles JJ, van den Berg HA, Skowera A, Cole DK, Dolton G, Schauenburg AJ, Tan MP, Pentier JM, Llewellyn-Lacey S, Miles KM, Bulek AM, Clement M, Williams T, Trimby A, Bailey M, Rizkallah P, Rossjohn J, Peakman M, Price DA, Burrows SR, Sewell AK, Wooldridge L.

Blood. 2013 Feb 14;121(7):1112-23. doi: 10.1182/blood-2012-06-437202. Epub 2012 Dec 18.

26.

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, Fenstermaker R, Pili R.

PLoS One. 2012;7(1):e30815. doi: 10.1371/journal.pone.0030815. Epub 2012 Jan 27.

27.

Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.

Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA, Pili R.

PLoS One. 2011;6(11):e27178. doi: 10.1371/journal.pone.0027178. Epub 2011 Nov 7.

28.

Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability.

Miles KM, Miles JJ, Madura F, Sewell AK, Cole DK.

Mol Immunol. 2011 Jan;48(4):728-32. doi: 10.1016/j.molimm.2010.11.004. Epub 2010 Dec 4.

29.

Design, synthesis and evaluation of β-lactam antigenic peptide hybrids; unusual opening of the β-lactam ring in acidic media.

Tarbe M, Azcune I, Balentová E, Miles JJ, Edwards EE, Miles KM, Do P, Baker BM, Sewell AK, Aizpurua JM, Douat-Casassus C, Quideau S.

Org Biomol Chem. 2010 Dec 7;8(23):5345-53. doi: 10.1039/c003877f. Epub 2010 Oct 7.

PMID:
20927455
30.

MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy.

Lindén SK, Sheng YH, Every AL, Miles KM, Skoog EC, Florin TH, Sutton P, McGuckin MA.

PLoS Pathog. 2009 Oct;5(10):e1000617. doi: 10.1371/journal.ppat.1000617. Epub 2009 Oct 9.

31.

Alcohol consumption among older adults in primary care.

Kirchner JE, Zubritsky C, Cody M, Coakley E, Chen H, Ware JH, Oslin DW, Sanchez HA, Durai UN, Miles KM, Llorente MD, Costantino G, Levkoff S.

J Gen Intern Med. 2007 Jan;22(1):92-7.

32.

Improving mental health assessment and service planning practices for older adults: a controlled comparison study.

Bartels SJ, Miles KM, Van Citters AD, Forester BP, Cohen MJ, Xie H.

Ment Health Serv Res. 2005 Dec;7(4):213-23.

PMID:
16320104
33.

Improving access to geriatric mental health services: a randomized trial comparing treatment engagement with integrated versus enhanced referral care for depression, anxiety, and at-risk alcohol use.

Bartels SJ, Coakley EH, Zubritsky C, Ware JH, Miles KM, Areán PA, Chen H, Oslin DW, Llorente MD, Costantino G, Quijano L, McIntyre JS, Linkins KW, Oxman TE, Maxwell J, Levkoff SE; PRISM-E Investigators.

Am J Psychiatry. 2004 Aug;161(8):1455-62.

PMID:
15285973
34.

Enhanced skills training and health care management for older persons with severe mental illness.

Bartels SJ, Forester B, Mueser KT, Miles KM, Dums AR, Pratt SI, Sengupta A, Littlefield C, O'Hurley S, White P, Perkins L.

Community Ment Health J. 2004 Feb;40(1):75-90.

PMID:
15077730
35.
36.

Design and sample characteristics of the PRISM-E multisite randomized trial to improve behavioral health care for the elderly.

Levkoff SE, Chen H, Coakley E, Herr EC, Oslin DW, Katz I, Bartels SJ, Maxwell J, Olsen E, Miles KM, Constantino G, Ware JH.

J Aging Health. 2004 Feb;16(1):3-27.

PMID:
14979308
37.
38.

Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups.

Mueser KT, Yarnold PR, Rosenberg SD, Swett C Jr, Miles KM, Hill D.

Schizophr Bull. 2000;26(1):179-92.

PMID:
10755680
39.

Mental health service use by elderly patients with bipolar disorder and unipolar major depression.

Bartels SJ, Forester B, Miles KM, Joyce T.

Am J Geriatr Psychiatry. 2000 Spring;8(2):160-6.

PMID:
10804077
40.

Conduct disorder, antisocial personality disorder and substance use disorders in schizophrenia and major affective disorders.

Mueser KT, Rosenberg SD, Drake RE, Miles KM, Wolford G, Vidaver R, Carrieri K.

J Stud Alcohol. 1999 Mar;60(2):278-84.

PMID:
10091967
41.

A comparative study of elderly patients with schizophrenia and bipolar disorder in nursing homes and the community.

Bartels SJ, Mueser KT, Miles KM.

Schizophr Res. 1997 Oct 30;27(2-3):181-90.

PMID:
9416647
42.

Antisocial personality disorder, conduct disorder, and substance abuse in schizophrenia.

Mueser KT, Drake RE, Ackerson TH, Alterman AI, Miles KM, Noordsy DL.

J Abnorm Psychol. 1997 Aug;106(3):473-7.

PMID:
9241949
43.

The course and treatment of substance use disorder in persons with severe mental illness.

Mueser KT, Drake RE, Miles KM.

NIDA Res Monogr. 1997;172:86-109. Review. No abstract available.

PMID:
9154267

Supplemental Content

Loading ...
Support Center